Assessment of Prevalence and Persistence of Human Papillomavirus (HPV) DNA in HIV-Infected Women Who Are Antiretroviral Naive and Have Initiated HAART

Inclusion Criteria

Inclusion Criteria

Women may be eligible for this study if they:

- Are HIV-positive.

- Are at least 13 years of age and menstruating.

- Are willing to enroll in another drug study.

- Have written consent of a parent or guardian if under 18 years.

- This study has been changed to increase enrollment. Women who are starting
HAART-based therapy prescribed by a personal physician or participating in an
antiretroviral trial are all eligible.

- Intend to start antiretroviral therapy within 14 days of study entry.

Exclusion Criteria

Women will not be eligible for this study if they:

- Have been on anti-HIV treatment for more than 14 days.

- Are abusing drugs or alcohol.

- Are receiving medication that affects the immune system, fights HPV, or is
investigational, except for anti-HIV drugs provided by coenrolling in a Phase II or
III trial with approval of a study chair within 30 days of study entry, including but
not limited to systemic interferons and interleukins, thalidomide, systemic
cidofovir, and HPV vaccines. This study has been changed. The following medications
are no longer excluded: thymopentin, hydroxyurea, granulocyte colony-stimulating
factor (G-CSF and filgrastim), and GM-CSF (sargramostim).

- Have cervical cancer or a history of cervical cancer.

- Have had a hysterectomy (removal of the uterus).

- Participated in HPV trials at any time.

- Use imiquimod inside the vagina.

- Are taking corticosteroid treatment in large doses.